Featured Research

from universities, journals, and other organizations

Successful repair of bone defects using novel tissue engineered bone graft

Date:
December 4, 2013
Source:
Society for Experimental Biology and Medicine
Summary:
In this study, scientists engineered a novel biomimetic tissue engineered bone graft with MSCs isolated from rabbit adipose, using collagen I hydrogel to encapsulate the -TCP scaffolds designed to enlarge the cells adhesion. The results demonstrated that the rabbit critical-sized bone defect could be completely repaired by the novel construct.

Researchers at the Department of Orthopaedics, of the Second Affiliated Hospital of Xi'an Jiaotong University Health Science Center, led by Dr. Kunzheng Wang and Dr. Pei Yang have developed a novel biomimetic tissue engineered bone graft based on rabbit adipose derived stem cells (rASCs), collagen I and a porous beta-tricalcium phosphate (β-TCP) scaffold. Furthermore, the critical-sized bone defects model of rabbits was used to evaluate the efficiency of the construct.

This discovery, reported in the December 2013 issue of Experimental Biology and Medicine, provides a novel candidate for bone defect repair.

Although bone has the capacity for regenerative growth and remodeling, these processes are often impaired in clinical situations in which loss of bone is caused by disease, trauma or tumor resection. More than 800,000 patients receive bone graft operations annually around the world. With the rapid development and progress of material and manufacturing sciences, tissue engineered bone grafting has become a promising technique in bone defect treatment. Bone tissue engineering involves three key factors: the seeding cell, growth factors and a porous scaffold. In the present study, rASCs were selected as the cell source for bone tissue engineering based upon the use of autologous ASCs for minimizing immunological rejection and the fact that greater cell numbers can be harvested from the patient with less pain. Collagen I was used to enhance the efficiency of cell adhesion. For the β-TCP scaffold the authors used a pore size of 460.9078.75 μm and interconnection pore size of 157.6637.94 μm. These were found to be biocompatible, osteoconductive, and able to be degraded, which facilitate vascularization and rapid bone growth progression. The in vivo experimental results demonstrated that the novel biomimetic tissue engineered bone graft could promote osteogenesis in critically sized defects. Twelve weeks after implantation, the defects were almost completely repaired by the presence of the cortical bone and medullary cavity. The results also suggested that the degeneration of the scaffolds may be accelerated by the interaction of rASCs, collagen I and the biomaterials.

"We hope to garner new insight into the engineering of rASCs-based bone tissue for clinical application." said Dr. Kunzheng Wang, senior author and Distinguished University Professor, Vice Chairmen of the Chinese Orthopaedic Association (COA).

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine, said "This exciting study by Professor Wang and his colleagues has provided a novel stem cell based and tissue engineered construct which can repair damaged bone. In the future these findings could be translated into the clinical setting."


Story Source:

The above story is based on materials provided by Society for Experimental Biology and Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. P. Yang, X. Huang, C. Wang, X. Dang, K. Wang. Repair of bone defects using a new biomimetic construction fabricated by adipose-derived stem cells, collagen I, and porous beta-tricalcium phosphate scaffolds. Experimental Biology and Medicine, 2013; 238 (12): 1331 DOI: 10.1177/1535370213505827

Cite This Page:

Society for Experimental Biology and Medicine. "Successful repair of bone defects using novel tissue engineered bone graft." ScienceDaily. ScienceDaily, 4 December 2013. <www.sciencedaily.com/releases/2013/12/131204182217.htm>.
Society for Experimental Biology and Medicine. (2013, December 4). Successful repair of bone defects using novel tissue engineered bone graft. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2013/12/131204182217.htm
Society for Experimental Biology and Medicine. "Successful repair of bone defects using novel tissue engineered bone graft." ScienceDaily. www.sciencedaily.com/releases/2013/12/131204182217.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins